Comparing Single‐agent with Doublet Chemotherapy in First‐line Treatment of Advanced Non‐small Cell Lung Cancer with Performance Status 2: A Meta‐analysis

Long Luo,Qian Hu,Jun‐xia Jiang,Xing Yang,Xiao‐xiao Dinglin,Xiao Lin,He‐rui Yao
DOI: https://doi.org/10.1111/ajco.12359
2015-01-01
Asia-Pacific Journal of Clinical Oncology
Abstract:AbstractAimThis systematic review and meta‐analysis was performed to assess the efficacy and side effects between single‐agent and doublet chemotherapy in first‐line treatment of advanced non‐small cell lung cancer with performance status 2 (PS2).MethodsWe searched for randomized controlled trials in online electronic databases and extracted data from eligible studies for meta‐analysis. Pooled hazard ratio (HR) for overall survival (OS), pooled risk difference (RD) for 1‐year survival, pooled risk ratio (RR) for objective response rate (ORR) and adverse effects were calculated using a fixed‐effect model.ResultsSix trials with 386 participants in the single‐agent group and 389 participants in the doublet group were included in this review. Compared with single‐agent chemotherapy, doublet significantly improved OS (HR 0.72; 95% CI 0.61–0.84; P < 0.0001) and significantly increased 1‐year survival rate (RD –0.09; 95% CI –0.14 to –0.03; P = 0.004) and ORR (RR 0.4; 95% CI 0.30–0.69; P = 0.0002). Doublet chemotherapy also significantly increased the risk of grade 3/4 neutropenia (RR = 4.97; 95% CI 2.93–8.43; P < 0.00001), thrombocytopenia (RR = 10.29; 95% CI 3.80–27.85; P < 0.00001) and anemia (RR = 2.50; 95% CI 1.27–4.90; P = 0.008).ConclusionsOur study implies that carboplatin‐containing doublet chemotherapy improved OS, 1‐year survival rate and ORR, but increased the risk of grade 3/4 hematotoxicity. Carboplatin‐containing doublet may well be superior to non‐carboplatin‐containing treatment.
What problem does this paper attempt to address?